News & Updates

Show Multimedia Only
Enzalutamide edges out abiraterone in mCRPC

Enzalutamide edges out abiraterone in mCRPC

15 Sep 2024 byJairia Dela Cruz

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.

15 Sep 2024